Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US. (Q38165803)

30 August 2017

title

Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US. (English)

1 reference

30 August 2017

main subject

prevention of HIV/AIDS

0 references

exposure assessment

1 reference

inferred from title

United States of America

1 reference

Fred J Hellinger

1

1 reference

30 August 2017

publication date

1 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

31

1 reference

30 August 2017

issue

12

1 reference

30 August 2017

page(s)

1091-1104

1 reference

Mortality among people who inject drugs: a systematic review and meta-analysis

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Estimation of HIV-testing rates to maximize early diagnosis-derived benefits at the individual and population level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Estimation of HIV incidence in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Estimated HIV Incidence in the United States, 2006–2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Successes and challenges of HIV prevention in men who have sex with men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Prevention of HIV-1 infection with early antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Supporting study product use and accuracy in self-report in the iPrEx study: next step counseling and neutral assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Breakthrough of the year. HIV treatment as prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Preexposure prophylaxis for HIV infection among African women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Combination prevention: new hope for stopping the epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Modelling sexual transmission of HIV: testing the assumptions, validating the predictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

A mathematical model of HIV dynamics in the presence of a rescuing virus with replication deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Stochastic models for virus and immune system dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Markov modelling of immunological and virological states in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Latent infection of CD4 T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

The cost effectiveness of combination antiretroviral therapy for HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

The future of HIV prevention in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Projected life expectancy of people with HIV according to timing of diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Impact of health care payer type on HIV stage of illness at time of initiation of antiretroviral therapy in the USA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40273-013-0111-0

Medical costs averted by HIV prevention efforts in the United States, 1991-2006

21 January 2018

1 reference

12 December 2020

Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States

1 reference

12 December 2020

Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men

1 reference

12 December 2020

The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men.

1 reference

12 December 2020

The Cost-Effectiveness of Pre-Exposure Prophylaxis in Men Who Have Sex With Men in the United States: An Epidemic Model

1 reference

12 December 2020

Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults

1 reference

12 December 2020

Epidemiology of HIV infection and AIDS in the United States

1 reference

12 December 2020

What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

1 reference

12 December 2020

Low nadir CD4 cell count predicts sustained hypertension in HIV-infected individuals

1 reference

12 December 2020

Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals

1 reference

12 December 2020

10.1007/S40273-013-0111-0

Identifiers

DOI

1 reference

30 August 2017

1 reference